Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CET
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
02/16JOHNSON & JOHNSON : New tremfya® (guselkumab) data demonstrates long-term skin c..
PU
02/16THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/16EAT.MOVE.CONNECT. TIP : New website offers personalized cancer info, support
AQ
02/16JOHNSON & JOHNSON : Consumer presents new scientific research at 2018 american a..
PU
02/16JOHNSON & JOHNSON : - ERLEADA, a Next-Generation Androgen Receptor Inhibitor Gra..
AQ
02/16JOHNSON & JOHNSON : williams, ronald a
PU
02/16JOHNSON & JOHNSON : washington, a. eugene
PU
02/16JOHNSON & JOHNSON : mulcahy, anne m
PU
02/16JOHNSON & JOHNSON : mcclellan, mark b.
PU
More news
News from SeekingAlpha
02/17STOCKS TO WATCH : Retail Heavyweights To Center Stage 
02/17RETIREMENT STRATEGY : Inflation Is A Scourge On Retirees' Well-Being 
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
02/16The Buffett We Don't Think To Learn From But Probably Should 
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,76%
P/E ratio 2018 18,20
P/E ratio 2019 17,01
EV / Sales 2018 4,49x
EV / Sales 2019 4,13x
Capitalization 353 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277